Department of Cardiology, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland.
Europace. 2010 Jan;12(1):64-70. doi: 10.1093/europace/eup362.
To describe the incidence and management of cardiac device infection. Infection is a serious, potentially fatal complication of device implantation. The numbers of device implants and infections are rising. Optimal care of device infection is not well defined.
We retrospectively identified cases of device infection at our institution between 2000 and 2007 by multiple source record review, and active surveillance. Device infection was related to demographics, clinical, and procedural characteristics. Descriptive analysis was performed. From 2000 to 2007, a total of 2029 permanent pacemakers and 1076 biventricular/implantable cardioverter-defibrillators (ICDs) or ICDs were implanted. Thirty-nine cases of confirmed device infections were identified--27 pacemaker and 12 bivent/ICD or ICD infections, giving an infection rate of 1.25%. Median time from implant or revision to presentation was 150 days (range 2915 days, IQR25% 35-IQR75% 731). Ninety percent of patients presented with generator-site infections. The most common organism was methicillin-sensitive Staphylococcus aureus (30.8%), followed by coagulase negative Staphylococcus (20.5%). Complete device extraction occurred in 82%. Of these, none had relapse, and mortality was 7.4% (n = 2/27). With partial removal or conservative therapy (n = 13), relapse occurred in 67% (n = 8/12), with mortality of 8.4% (n = 1/12). Median duration of antibiotics was 42 days (range 47 days, IQR25% 28-IQR75% 42 days). Re-implantation of a new device occurred in 54%, at a median of 28 days (range 73 days, IQR25% 8.5-IQR75% 35 days). Methicillin-Resistant Staphylococcus Aureus infection predicted mortality (P < 0.004, RR 37, 95% CI 5.3-250). Median follow-up was 36 months.
Cardiac device infection is a rare complication, with significant morbidity and mortality. Complete hardware removal with appropriate duration of antimicrobial therapy results in the best outcomes for patients.
描述心脏器械感染的发生率和处理方法。感染是器械植入的严重潜在致命并发症。器械植入和感染的数量正在增加。器械感染的最佳治疗方法尚未明确。
我们通过多源记录回顾和主动监测,回顾性确定了 2000 年至 2007 年期间我院的器械感染病例。器械感染与人口统计学、临床和程序特征有关。进行了描述性分析。2000 年至 2007 年期间,共植入 2029 个永久性起搏器和 1076 个双心室/植入式心脏复律除颤器(ICD)或 ICD。确定了 39 例确诊的器械感染病例,其中 27 例为起搏器感染,12 例为双心室/ICD 或 ICD 感染,感染率为 1.25%。从植入或修订到出现的中位时间为 150 天(范围 2915 天,IQR25% 35-IQR75% 731)。90%的患者出现发生器部位感染。最常见的病原体是甲氧西林敏感的金黄色葡萄球菌(30.8%),其次是凝固酶阴性葡萄球菌(20.5%)。82%的患者完全取出了器械。其中,无一例复发,死亡率为 7.4%(n=2/27)。对于部分取出或保守治疗(n=13),67%(n=8/12)复发,死亡率为 8.4%(n=1/12)。抗生素的中位持续时间为 42 天(范围 47 天,IQR25% 28-IQR75% 42 天)。54%的患者重新植入了新的器械,中位时间为 28 天(范围 73 天,IQR25% 8.5-IQR75% 35 天)。耐甲氧西林金黄色葡萄球菌感染预测死亡率(P<0.004,RR 37,95%CI 5.3-250)。中位随访时间为 36 个月。
心脏器械感染是一种罕见的并发症,具有显著的发病率和死亡率。彻底清除硬件并辅以适当时间的抗菌治疗可使患者获得最佳结局。